SSMF grant supports study of metabolic health and brain ageing
April 7, 2026 / Metabolic Syndrome Dementia / Brain Aging Research / Cardiometabolic Risk Factors / Cognitive Decline Prevention / Neuroimaging Biomarkers
A funded study will investigate how metabolic syndrome components—obesity, hyperglycemia, and hypertension—drive brain aging and dementia risk, leveraging longitudinal imaging and biomarker data to identify mechanisms and prevention targets.
Racial and ethnic variations of metabolic indicators associated with childhood obesity: a comparative cross-sectional study
April 9, 2026 / Childhood Obesity Disparities / Ethnic Metabolic Differences / Insulin Resistance Pediatrics / ACTH Hormonal Pathways / Cardiometabolic Risk Factors
Multiethnic analysis shows childhood obesity drives distinct metabolic profiles across racial groups, with variations in insulin resistance and lipid markers; ACTH may mediate metabolic dysfunction in Chinese adolescents, supporting the need for ethnicity-specific prevention strategies.
Heart, metabolic and inflammatory risk patterns found to differ markedly between men and women with obesity
April 12, 2026 / Obesity Sex Differences / Visceral Fat Risk / Inflammatory Biomarkers / Cardiometabolic Disease / Gender Specific Treatment
Sex-based differences in obesity show men have higher visceral fat and liver risk, while women exhibit greater inflammation and dyslipidemia, underscoring the need for gender-specific strategies in managing cardiometabolic and inflammatory complications.
Men and women with obesity face very different hidden health risks
April 13, 2026 / Obesity Gender Differences / Visceral Fat Liver Risk / Inflammatory Markers Women / Cholesterol Cardiometabolic Risk / Personalized Obesity Treatment
Obesity presents sex-specific risks, with men prone to visceral fat and liver dysfunction, while women exhibit higher inflammation and cholesterol, emphasizing the importance of personalized, gender-specific approaches to managing cardiometabolic health.
Popular sweeteners may impact metabolism across generations
April 10, 2026 / Non Nutritive Sweeteners / Gut Microbiome Metabolism / Insulin Resistance Risk / Epigenetic Inheritance / Cardiometabolic Health
Preclinical data suggest non-nutritive sweeteners like sucralose and stevia may alter gut microbiome composition, gene expression, and glucose metabolism, with potential transgenerational effects, raising concerns about long-term cardiometabolic risk.
Aelis Farma Awarded a €458k Grant Under France 2030 in Nouvelle-Aquitaine to Support Development of Its Program in Obesity and Associated Metabolic Diseases
April 7, 2026 / CB1 Receptor Inhibitors / Obesity Drug Development / Metabolic Disease Therapy / Endocannabinoid System / Preclinical Biopharma Research
Aelis Farma received €458k funding to advance CB1 receptor-targeted therapies for obesity and metabolic diseases, supporting preclinical development of novel signaling inhibitors with potential to address underlying metabolic dysregulation.
Probiotics may boost effectiveness of GLP-1 drugs in obesity treatment, study finds
April 9, 2026 / GLP 1 Therapy Enhancement / Probiotics Obesity Treatment / Gut Microbiome Metabolism / Weight Regain Prevention / Glycemic Control Improvement
Preclinical evidence suggests probiotics may enhance GLP-1 receptor agonist efficacy, improving weight loss, glycemic control, and preventing weight regain via microbiome-driven metabolic pathways, highlighting a potential adjunct strategy in obesity management.
Healthy obesity does not exist, even with perfect exams the risk of illness and death increases: the study
April 10, 2026 / Metabolically Healthy Obesity / Cardiovascular Risk Obesity / Fatty Liver Disease Risk / Obesity Mortality Risk / Metabolic Health Misconceptions
Evidence refutes “metabolically healthy obesity,” showing elevated risks of cardiovascular disease, heart failure, fatty liver, and mortality despite normal metabolic markers, reinforcing obesity as an independent disease requiring early intervention.
Sirka Strengthens Metabolic Service Ecosystem through Clinic and Technology Expansion
April 12, 2026 / Digital Health Obesity Care / Metabolic Disease Management / Integrated Obesity Treatment / Cardiometabolic Health Monitoring / Chronic Disease Management
Sirka expands clinic and digital health services to deliver integrated obesity care, combining lifestyle, pharmacologic therapy, and continuous monitoring, improving cardiometabolic outcomes and reinforcing obesity as a chronic disease requiring data-driven, early intervention strategies.
Tamil Nadu faces tri burden of obesity, anaemia and metabolic disorders: Apollo report
April 7, 2026 / Obesity Epidemic India / Metabolic Disorders Prevalence / Anemia Public Health / Cardiometabolic Risk Screening / Preventive Healthcare India
Large-scale screening in Tamil Nadu reveals a high co-prevalence of obesity, anaemia, and metabolic disorders, often asymptomatic and emerging early, highlighting the need for predictive, preventive care to reduce cardiometabolic risk and improve population health outcomes.
Global Surge in Metabolic Liver Disease Demands Urgent Action
April 14, 2026 / MASLD Global Burden / Fatty Liver Disease / Metabolic Liver Disease / Cardiometabolic Risk / Global Health Trends
Metabolic dysfunction-associated steatotic liver disease (MASLD) is rapidly rising globally, affecting 1.3 billion people, with projections reaching 1.8 billion by 2050, disproportionately impacting younger populations in low- and middle-income countries and driving urgent need for intervention.
Cholesterol regulatory genes predict liver transplant outcomes
April 10, 2026 / Liver Transplant Outcomes / Cholesterol Metabolism Genes / MASLD MASH / Graft Dysfunction Risk / SREBF2 HMGCR
Elevated cholesterol and fatty acid levels, along with increased SREBF2 and HMGCR gene expression in donor livers, are associated with higher risk of graft dysfunction, transplant failure, and mortality, highlighting their value in improving liver transplant selection and outcomes.
New ALF board chair turned personal loss from MASH into public advocacy
April 13, 2026 / MASH Liver Disease / Liver Disease Awareness / Metabolic Liver Advocacy / Steatotic Liver Disease / Public Health Liver
New ALF chair David Frank, motivated by personal loss from MASH, aims to expand liver disease awareness, early detection, and advocacy, particularly in high-risk and underserved populations, addressing the growing public health burden of metabolic liver disease.
A Natural Hormone Targets the Same Brain Area As GLP-1
April 13, 2026 / FGF21 Hormone Therapy / Obesity Brain Pathways / GLP1 vs FGF21 / Metabolic Regulation Brain / MASH Treatment Research
FGF21, a naturally occurring hormone, reduces obesity in mice by targeting hindbrain metabolic pathways, distinct from GLP-1 appetite suppression, highlighting a novel mechanism with therapeutic potential for obesity and MASH.
JW Pharmaceutical signs $81 mil. license-in deal with China’s Gan & Lee for GLP-1 obesity drug
April 9, 2025 / GLP1 Obesity Drug / Bofanglutide GZR18 / Metabolic Disease Therapy / Obesity Pharmacotherapy / GLP1 Receptor Agonist
JW Pharmaceutical licensed GLP-1 receptor agonist bofanglutide from Gan & Lee, advancing obesity therapeutics in Korea, with potential to expand metabolic disease treatment options pending regulatory approval and clinical validation.
Korean researchers link gut microbes to chronic liver disease
April 10, 2026 / Gut Liver Axis / MASH Diagnosis AI / Microbiome Liver Disease / Noninvasive Liver Testing / Metabolic Liver Disease
Gut microbiota, particularly Romboutsia hominis, drive MASH progression via inflammatory pathways, while beneficial microbes may counteract disease. A machine learning model using microbiome and blood data enables accurate, noninvasive diagnosis and highlights therapeutic targets in the gut-liver axis.
Madrigal Pharmaceuticals Grants Inducement Awards to New Employees
April 8, 2026 / MASH Drug Development / Metabolic Liver Disease / Biopharma Talent Strategy / Rezdiffra Clinical Trials / Pharmaceutical Workforce Expansion
Madrigal Pharmaceuticals issued equity inducement awards to new employees to support workforce expansion as it advances its MASH therapy pipeline, underscoring ongoing investment in talent to drive development of treatments for metabolic liver disease.
Heart, metabolic and inflammatory risk patterns found to differ markedly between men and women with obesity
April 12, 2026 / Sex Differences Obesity / Cardiometabolic Risk / Visceral Fat Liver Disease / Inflammation Dyslipidemia / Personalized Obesity Treatment
Obesity presents sex-specific cardiometabolic risks, with men showing increased visceral fat and liver dysfunction, while women exhibit higher systemic inflammation and dyslipidemia, underscoring the need for gender-tailored prevention and treatment strategies.
Men and women with obesity face very different hidden health risks
April 13, 2025 / Sex Differences Obesity / Visceral Fat Risk / Inflammation Cholesterol / Liver Dysfunction Obesity / Personalized Metabolic Care
Obesity exhibits sex-specific risk profiles, with men prone to visceral fat and liver dysfunction, while women show higher inflammation and cholesterol, highlighting biological differences that may guide more personalized cardiometabolic treatment strategies.